AstraZeneca (AZN) PT Set at GBX 6,500 by Barclays

AstraZeneca (LON:AZN) has been assigned a GBX 6,500 ($84.14) price objective by research analysts at Barclays in a report issued on Friday, July 27th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays’ price objective points to a potential upside of 6.44% from the stock’s previous close.

A number of other analysts have also weighed in on AZN. Berenberg Bank set a GBX 6,000 ($77.67) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, April 24th. Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a report on Monday, April 9th. Jefferies Financial Group set a GBX 5,650 ($73.14) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th. JPMorgan Chase & Co. set a GBX 5,500 ($71.20) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 22nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of GBX 5,577.36 ($72.20).

Shares of AstraZeneca traded up GBX 31 ($0.40), hitting GBX 6,107 ($79.06), during midday trading on Friday, according to MarketBeat.com. The company’s stock had a trading volume of 1,938,710 shares, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.15) and a one year high of GBX 5,520 ($71.46).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: What does RSI mean?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply